Cargando…

Quality by Design Approach in Liposomal Formulations: Robust Product Development

Nanomedicine is an emerging field with continuous growth and differentiation. Liposomal formulations are a major platform in nanomedicine, with more than fifteen FDA-approved liposomal products in the market. However, as is the case for other types of nanoparticle-based delivery systems, liposomal f...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshaer, Walhan, Nsairat, Hamdi, Lafi, Zainab, Hourani, Omar M., Al-Kadash, Abdulfattah, Esawi, Ezaldeen, Alkilany, Alaaldin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822211/
https://www.ncbi.nlm.nih.gov/pubmed/36615205
http://dx.doi.org/10.3390/molecules28010010
_version_ 1784865890105294848
author Alshaer, Walhan
Nsairat, Hamdi
Lafi, Zainab
Hourani, Omar M.
Al-Kadash, Abdulfattah
Esawi, Ezaldeen
Alkilany, Alaaldin M.
author_facet Alshaer, Walhan
Nsairat, Hamdi
Lafi, Zainab
Hourani, Omar M.
Al-Kadash, Abdulfattah
Esawi, Ezaldeen
Alkilany, Alaaldin M.
author_sort Alshaer, Walhan
collection PubMed
description Nanomedicine is an emerging field with continuous growth and differentiation. Liposomal formulations are a major platform in nanomedicine, with more than fifteen FDA-approved liposomal products in the market. However, as is the case for other types of nanoparticle-based delivery systems, liposomal formulations and manufacturing is intrinsically complex and associated with a set of dependent and independent variables, rendering experiential optimization a tedious process in general. Quality by design (QbD) is a powerful approach that can be applied in such complex systems to facilitate product development and ensure reproducible manufacturing processes, which are an essential pre-requisite for efficient and safe therapeutics. Input variables (related to materials, processes and experiment design) and the quality attributes for the final liposomal product should follow a systematic and planned experimental design to identify critical variables and optimal formulations/processes, where these elements are subjected to risk assessment. This review discusses the current practices that employ QbD in developing liposomal-based nano-pharmaceuticals.
format Online
Article
Text
id pubmed-9822211
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98222112023-01-07 Quality by Design Approach in Liposomal Formulations: Robust Product Development Alshaer, Walhan Nsairat, Hamdi Lafi, Zainab Hourani, Omar M. Al-Kadash, Abdulfattah Esawi, Ezaldeen Alkilany, Alaaldin M. Molecules Review Nanomedicine is an emerging field with continuous growth and differentiation. Liposomal formulations are a major platform in nanomedicine, with more than fifteen FDA-approved liposomal products in the market. However, as is the case for other types of nanoparticle-based delivery systems, liposomal formulations and manufacturing is intrinsically complex and associated with a set of dependent and independent variables, rendering experiential optimization a tedious process in general. Quality by design (QbD) is a powerful approach that can be applied in such complex systems to facilitate product development and ensure reproducible manufacturing processes, which are an essential pre-requisite for efficient and safe therapeutics. Input variables (related to materials, processes and experiment design) and the quality attributes for the final liposomal product should follow a systematic and planned experimental design to identify critical variables and optimal formulations/processes, where these elements are subjected to risk assessment. This review discusses the current practices that employ QbD in developing liposomal-based nano-pharmaceuticals. MDPI 2022-12-20 /pmc/articles/PMC9822211/ /pubmed/36615205 http://dx.doi.org/10.3390/molecules28010010 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alshaer, Walhan
Nsairat, Hamdi
Lafi, Zainab
Hourani, Omar M.
Al-Kadash, Abdulfattah
Esawi, Ezaldeen
Alkilany, Alaaldin M.
Quality by Design Approach in Liposomal Formulations: Robust Product Development
title Quality by Design Approach in Liposomal Formulations: Robust Product Development
title_full Quality by Design Approach in Liposomal Formulations: Robust Product Development
title_fullStr Quality by Design Approach in Liposomal Formulations: Robust Product Development
title_full_unstemmed Quality by Design Approach in Liposomal Formulations: Robust Product Development
title_short Quality by Design Approach in Liposomal Formulations: Robust Product Development
title_sort quality by design approach in liposomal formulations: robust product development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822211/
https://www.ncbi.nlm.nih.gov/pubmed/36615205
http://dx.doi.org/10.3390/molecules28010010
work_keys_str_mv AT alshaerwalhan qualitybydesignapproachinliposomalformulationsrobustproductdevelopment
AT nsairathamdi qualitybydesignapproachinliposomalformulationsrobustproductdevelopment
AT lafizainab qualitybydesignapproachinliposomalformulationsrobustproductdevelopment
AT houraniomarm qualitybydesignapproachinliposomalformulationsrobustproductdevelopment
AT alkadashabdulfattah qualitybydesignapproachinliposomalformulationsrobustproductdevelopment
AT esawiezaldeen qualitybydesignapproachinliposomalformulationsrobustproductdevelopment
AT alkilanyalaaldinm qualitybydesignapproachinliposomalformulationsrobustproductdevelopment